Q-omics provides the consensus-scored ZNF792 profile across patient tissues and cancer cell-line models. ZNF792 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF792 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ZNF792 RNA expression shows 20,506 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, COAD, and KIRP as cancer lineages where ZNF792 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF792 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF792 survival associations across molecular data types. ZNF792 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF792 RNA expression–survival associations across cancer types. High ZNF792 expression shows unfavorable associations in LIHC and LGG, but favorable associations in KIRC, BRCA, COAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF792 RNA expression.
This table summarizes ZNF792 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF792. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF792 shows lower tumor expression in LUSC and KICH and higher tumor expression in COAD, KIRC, STAD and LIHC. The COAD box plot shows higher ZNF792 RNA expression in tumor versus normal tissue (log2 FC = +1.152, t-test p < 0.001).
This table shows molecular features associated with ZNF792 in patient tissues and cancer cell lines. In patient samples, ZNF792 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF792 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
